Healthcare

Pro Medicus Shares Rise Following AU$30 Million Contract with Duly H...

Highlights,AU$30 Million Contract Signed:,Pro Medicus secures a seven-year deal with Duly Health and Care, the largest physician-directed medical grou...

FDA Clears Prescient Therapeutics (ASX:PTX) for Phase 2 PTX-100 Tria...

Highlights,Prescient Therapeutics (PTX) receives FDA clearance for a Phase 2 trial of PTX-100.,The trial focuses on relapsed and refractory cutaneous...

Pro Medicus Expands U.S. Presence with $30m Deal

Highlights,Pro Medicus (PME) secures a long-term partnership with Duly Health and Care.,The $30m agreement focuses on implementing advanced cloud imag...

Integral Diagnostics Completes Merger with Capitol Health, Appoints...

Highlights,Merger Completion:,Integral Diagnostics (ASX: IDX) has completed its merger with Capitol Health (ASX: CAJ) through a scheme of arrangement....

Little Green Pharma to Acquire Health House Australia for AU$1.25Mn

Highlights,Strategic Acquisition:,Little Green Pharma signs a binding letter of intent to acquire Health House Australia Pty Ltd for $1.25 million.,Re...

Radiopharm Theranostics Advances with Phase 1 Cancer Trial Approval

Highlights,Radiopharm,Theranostics,(RAD) secures ethics approval for a Phase 1 cancer trial,.,The trial targets HER2-positive cancers using the novel...

Radiopharm Theranostics Receives Approval for Lu-RAD202 Clinical Tri...

Highlights,Radiopharm Theranostics Ltd (ASX:RAD) has gained ethics approval to commence Phase 1 trials for Lu-RAD202, a candidate treatment for HER2-p...

Mesoblast (ASX:MSB) Gains Momentum with FDA Approval for Ryoncil The...

Highlights,FDA approval boosts Mesoblast (MSB) with new therapy Ryoncil.,Ryoncil marks the first approved therapy for SR-aGvHD in the US.,Mesoblast se...

Mesoblast's (ASX:MSB) Ryoncil Secures Historic FDA Approval for SR-a...

Highlights,Ryoncil,becomes the first FDA-approved mesenchymal stromal cell therapy for SR-,aGvHD,.,Mesoblast (,ASX:MSB,) expands treatment options for...

Breakthrough: Mesoblast (ASX:MSB) Gains FDA Approval for First MSC T...

Highlights,Mesoblast (MSB) secures FDA approval for RYONCIL®,.,RYONCIL,becomes,the first mesenchymal stromal cell therapy approved in the US,.,Signifi...

Austco Healthcare Limited (ASX:AHC): Examining Performance Metrics A...

Highlights:,Austco Healthcare Limited (,ASX:AHC,) has a price-to-earnings (P/E) ratio of 13.9x, significantly lower than the broader Australian market...

LTR Pharma Partners with Men’s Health Downunder for Erectile Dysfunc...

Highlights,LTR Pharma partners with MHDU to introduce SPONTAN, a nasal spray for erectile dysfunction.,Collaboration provides access to MHDU’s extensi...

Mesoblast Shares Surge 33% as FDA Approves Groundbreaking RYONCIL® T...

Highlights,FDA approves Mesoblast’s RYONCIL® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S.,RYONCIL becomes the only ap...

Orthocell (ASX:OCC) Advances Nerve Repair Innovation with FDA Submis...

Highlights,Orthocell,(OCC),submits,FDA application for,Remplir,™, targeting the expansive US nerve repair market,.,Successful study positions,Remplir,...

Cochlear (ASX:COH) Shares: Why Healthcare Stocks are Attracting Atte...

Highlights,Cochlear (COH) focuses on advanced hearing solutions with stable revenue growth,.,The healthcare sector,demonstrates,resilience in challeng...

Percheron Therapeutics (ASX:PER) Shares Phase IIb Duchenne Results

Highlights,Percheron Therapeutics (PER) announces Phase IIb trial results of,avicursen,in DMD,.,The trial did not meet its primary efficacy endpoint b...

Innovative Psilocybin Therapy Shows Promise in Phase 2a IBS Trial

Highlights,Promising interim results for TRP-8802 in IBS trial at Massachusetts General Hospital,.,TRP-8803 highlighted as a potential treatment with...

Clarity Pharmaceuticals (ASX:CU6) Launches New Cancer Radiopharmaceu...

Highlights,Clarity Pharmaceuticals (CU6) advances a new radiopharmaceutical, SAR-,bisFAP,The product targets multiple cancers with diagnostic and trea...

Ramsay Health Care (ASX:RHC) Faces Five-Year Decline in Share Price...

Highlights,Ramsay Health Care (RHC) faces long-term stock decline,.,Earnings per share (EPS) fell annually over the last five years,.,Total shareholde...

Actinogen Medical (ASX:ACW) Faces Challenges Despite Strong Revenue...

Highlights,Actinogen Medical (ACW) shares experienced significant volatility over the past three years.,Revenue growth has been substantial but share...